Health
Health

Lung Cancer: Screening, Symptoms, Targeted Therapy & Non-Smoker Risks

Lung cancer is the uncontrolled growth of abnormal cells in the airways and air sacs, affecting both smokers and non-smokers. Because nearly 95% of Malaysian cases are diagnosed late, low-dose CT screening and targeted therapy are vital for improving early detection and stage 4 survival.
Author Bowtie Team
Date 2026-11-09
Updated on 2026-11-09
Share

Lung Cancer: How Lung Function Works & Key Warning Signs

Healthy lungs rely on branching airways and microscopic air sacs to transfer oxygen into the bloodstream and expel carbon dioxide. Lung cancer develops when cells lining these passages mutate and multiply uncontrollably, forming solid tumours that block airflow, reduce breathing capacity, and trigger fluid accumulation around the lungs. Because the lungs have few pain receptors and a large functional reserve, early tumours rarely cause pain or noticeable breathing difficulties until the disease is already advanced.

Understanding how normal respiratory anatomy breaks down helps explain why symptoms often appear late:

  • Basic Concept of Lung Function: When you inhale, air travels down the windpipe (trachea) into two main bronchi, which branch into smaller bronchioles and end in millions of tiny air sacs called alveoli. These alveoli pass oxygen into surrounding blood vessels while removing carbon dioxide.
  • How Tumours Obstruct Airways: Rapidly dividing cancer cells form masses that narrow or block the bronchi and bronchioles. As tumours invade surrounding tissue and lymphatics, they reduce lung capacity and can cause fluid to build up in the chest cavity, a condition known as pleural effusion.
  • Primary Classifications: Oncologists classify the disease into two main types based on how the cells look under a microscope:
    • Non-Small Cell Lung Cancer (NSCLC): Accounts for 80% to 85% of all cases. The most common subtype in Malaysia is adenocarcinoma, which typically starts in the outer mucus-producing cells of the lungs and grows more slowly.
    • Small Cell Lung Cancer (SCLC): Accounts for 10% to 15% of cases. It grows and spreads (metastasises) much faster than NSCLC and is strongly linked to heavy tobacco exposure.
  • Key Warning Signs: Common symptoms include a persistent cough lasting more than three weeks, coughing up blood or rust-coloured phlegm (haemoptysis), unexplained breathlessness, recurrent chest infections, hoarseness, and persistent chest or shoulder pain. In Malaysia, because these warning signs are frequently mistaken for routine infections or ageing, approximately 90% to 95% of lung cancer cases are only detected at Stage 3 or Stage 4.

Breaking Stereotypes: Lung Cancer in Non-Smokers in Malaysia & Vaping Risks

While cigarette smoking remains a major cause of respiratory malignancy, lung cancer in non-smokers in Malaysia accounts for a substantial and growing proportion of local diagnoses, particularly among Asian women. Unlike smoking-related tumours that typically develop in the central airways, lung cancer in never-smokers is predominantly adenocarcinoma located in the outer edges of the lungs, driven by acquired genetic mutations and chronic environmental exposures rather than personal tobacco use.

Moving beyond traditional stereotypes is essential for public awareness. If you have never smoked, assuming you have zero risk can delay vital medical checks when a cough or chest ache lingers. In Malaysia and across East and Southeast Asia, clinical studies show that between 39% and over 60% of patients with lung adenocarcinoma harbour mutations in the Epidermal Growth Factor Receptor (EGFR) gene, with significantly higher rates observed in female never-smokers. These genetic changes are acquired during a person’s lifetime—not inherited at birth—and act like a stuck accelerator pedal, signalling lung cells to divide continuously.

Several environmental and lifestyle factors also contribute to non-smoker lung cancer and emerging respiratory risks:

  • Secondhand Smoke Exposure: Breathing in sidestream smoke at home, workplaces, or eateries exposes non-smokers to the same carcinogenic compounds inhaled by active smokers.
  • Air Pollution and Seasonal Haze: Fine particulate matter (PM2.5) from vehicle exhaust, industrial emissions, and transboundary haze can penetrate deep into the alveoli, causing chronic inflammation and cellular DNA changes.
  • Indoor Cooking Oil Fumes: High-temperature wok cooking in poorly ventilated kitchens releases volatile organic compounds and polycyclic aromatic hydrocarbons, which epidemiological studies link to higher adenocarcinoma rates among non-smoking women.
  • Occupational Hazards: Long-term workplace exposure to asbestos fibres, silica dust, diesel exhaust, or naturally occurring radon gas increases cellular damage in the lung lining.
  • Evaluating Vaping and Lung Cancer Risk: Many Malaysians view electronic cigarettes as a harmless alternative to conventional cigarettes because vaping does not burn tobacco leaf or produce tar. However, evaluating vaping and lung cancer risk requires looking closely at what e-cigarette aerosols actually contain. Heating e-liquids generates ultrafine particles, volatile organic compounds (such as benzene), carcinogenic aldehydes (including formaldehyde, acetaldehyde, and acrolein), and trace heavy metals like nickel, tin, chromium, and lead leached from heating coils. Inhaling these substances deep into the lungs triggers chronic airway inflammation, oxidative stress, and cellular DNA damage—biological mechanisms directly linked to long-term cancer development.

Early Detection: Low-Dose CT Lung Screening in Malaysia

Low-dose CT lung screening in Malaysia is a rapid, painless, and non-invasive 3D imaging scan that uses minimal radiation to detect tiny lung nodules long before physical symptoms surface. Because standard two-dimensional chest X-rays frequently miss sub-centimetre tumours hidden behind the heart, ribs, or diaphragm, Low-Dose Computed Tomography (LDCT) is recognised by Malaysian respiratory specialists and international health bodies as the gold standard for early lung cancer detection.

Catching lung cancer at Stage 1—when a tumour is small and confined to the lung—results in a five-year survival rate of 70% to 90%. In contrast, Malaysia’s overall five-year relative survival rate across all stages sits at roughly 11%, largely because most patients only seek medical attention when advanced tumours cause severe symptoms.

Proactive screening is designed to achieve a “stage shift,” identifying abnormalities while they can still be cured with minimally invasive surgery. According to local screening guidelines and hospital protocols in Malaysia, an LDCT scan is generally recommended for:

  • Adults aged 45 to 75 years (or 50 to 80 years under certain hospital criteria) who are current smokers, long-term vapers, or former smokers who quit within the past 15 years.
  • Non-smokers with a family history of lung cancer in a first-degree relative (parent, sibling, or child).
  • Individuals with chronic environmental or occupational exposure to secondhand smoke, asbestos, or industrial pollutants.
  • Patients with an abnormal or inconclusive Chest X-Ray (including AI-assisted chest radiographs conducted at primary care clinics) who require 3D confirmation.

LDCT vs. Standard Chest X-Ray: Diagnostic Accuracy and Estimated Costs

When deciding on a health check-up in Malaysia, many people assume a standard chest X-ray included in basic wellness packages is sufficient to rule out lung cancer. However, a standard X-ray compresses the entire chest into a single flat image, making it difficult to spot early, translucent nodules.

The table below compares Low-Dose CT (LDCT) lung screening against a standard Chest X-Ray across diagnostic performance and estimated private healthcare pricing in Malaysia:

Feature / Metric Low-Dose CT (LDCT) Lung Scan Standard Chest X-Ray (CXR)
Diagnostic Accuracy & Sensitivity High sensitivity; proven in clinical trials to reduce lung cancer mortality by catching Stage 1 tumours. Low sensitivity for early-stage cancer; often misses small or non-calcified nodules until they grow large.
Minimum Nodule Size Detected Can detect tiny lung nodules as small as 2 mm to 5 mm (sub-centimetre). Typically only detects masses 10 mm (1 cm) or larger, and often misses lesions behind bones or the heart.
Imaging Dimension 3D cross-sectional slices providing a complete, unobstructed view of lung tissue. 2D flat projection where ribs, collarbones, heart, and diaphragm overlap lung tissue.
Radiation Dose Low radiation (approx. 1.0 to 1.5 mSv), which is up to 75%–90% less than a conventional diagnostic CT scan. Very low radiation (approx. 0.02 to 0.1 mSv).
Scan Duration & Preparation Takes less than 1 to 2 minutes in a scanner; requires no fasting and no intravenous (IV) contrast dye. Takes a few seconds standing against a plate; no preparation required.
Estimated Cost in Malaysia (Private) RM430 – RM700 (standalone promotional or wellness screening packages at private hospitals). RM50 – RM105 (at private clinics, diagnostic centres, or hospitals).

Finding a Lung Cancer Specialist in Malaysia & Stage 4 Targeted Therapy

Navigating a suspected lung cancer diagnosis requires consulting a multidisciplinary team of lung cancer specialists in Malaysia to confirm the exact cell type, stage the disease, and run genetic biomarker tests. For patients diagnosed at an advanced stage, stage 4 lung cancer targeted therapy uses precision oral medications—such as Tyrosine Kinase Inhibitors (TKIs)—to block specific genetic mutations driving tumour growth, offering better disease control and fewer side effects than traditional chemotherapy.

Modern lung cancer care in Malaysia is not handled by a single doctor in isolation. Instead, major public tertiary hospitals and private oncology centres rely on a coordinated pathway involving several specialists:

  1. Respiratory Physician (Pulmonologist): Usually the first specialist you see after an abnormal scan. The pulmonologist evaluates your breathing function and performs a bronchoscopy (passing a thin camera down the airways) or coordinates a CT-guided needle biopsy to collect a tissue sample.
  2. Pathologist and Molecular Diagnostics Team: Examines the biopsied tissue or a “liquid biopsy” (blood test looking for circulating tumour DNA) to confirm whether the cancer is NSCLC or SCLC. Crucially, they perform molecular profiling—such as Next-Generation Sequencing (NGS) or PCR testing—to check for actionable driver mutations like EGFR, ALK, ROS1, BRAF, MET, or KRAS, alongside PD-L1 protein levels.
  3. Cardiothoracic Surgeon: Specialises in chest surgery. If the cancer is caught early (Stage 1 or Stage 2, and selected Stage 3A cases), a cardiothoracic surgeon can perform curative resection—often using minimally invasive Video-Assisted Thoracoscopic Surgery (VATS) or robotic surgery—to remove the affected lung lobe.
  4. Clinical or Medical Oncologist: Leads systemic treatment for locally advanced (Stage 3) and metastatic (Stage 4) lung cancer, as well as pre- or post-surgical therapy. The oncologist designs a personalised regimen using targeted therapy, immunotherapy, chemotherapy, or precision radiotherapy.

How Stage 4 Lung Cancer Targeted Therapy Works

Historically, Stage 4 lung cancer—where cancer cells have spread beyond the primary lung to distant sites like the other lung, bones, brain, or liver—was treated almost exclusively with intravenous chemotherapy. While chemotherapy destroys rapidly dividing cancer cells, it also attacks healthy dividing cells in the hair follicles, digestive tract, and bone marrow, leading to fatigue, nausea, hair loss, and lowered immunity.

Targeted therapy has transformed how Stage 4 NSCLC is managed, especially for Malaysian patients whose tumours test positive for an actionable mutation like EGFR or ALK:

  • Precision Mechanism: Think of a genetic mutation like a faulty switch inside the cancer cell that is permanently turned “on,” telling the cell to multiply endlessly. Targeted therapies, predominantly oral Tyrosine Kinase Inhibitors (TKIs), are designed to fit into that specific molecular switch and lock it in the “off” position, halting tumour growth and causing existing tumours to shrink.
  • Oral Convenience: Most TKIs are taken at home as a daily pill rather than requiring hours on an intravenous drip in a hospital daycare ward.
  • Preserving Healthy Tissue and Quality of Life: Because targeted drugs zero in on mutated cancer cells and largely spare normal, healthy cells, side effects are typically milder and more manageable (such as dry skin, mild rash, or diarrhoea) compared to conventional chemotherapy. Many patients on targeted therapy continue working and maintaining their normal daily routines for years.

How Medical Insurance and Critical Illness Cover Lung Cancer Treatments

Treating advanced lung cancer in Malaysia involves substantial, ongoing medical expenses, as stage 4 targeted therapies and immunotherapies often cost several thousand Ringgit every month. Having both a comprehensive medical insurance card and a Critical Illness (CI) plan provides the financial stamina needed for long-term oncology treatments, covering hospital bills while replacing lost household income.

Because modern precision medicine turns advanced lung cancer from an acute crisis into a managed, long-term condition, patients frequently stay on daily oral targeted medication for years. Understanding the financial reality and how different insurance policies respond is vital for protecting your family’s savings:

  • The High Cost of Advanced Care in Malaysia: Before treatment even begins, a thorough diagnostic workup—including a PET-CT staging scan, bronchoscopy biopsy, and comprehensive Next-Generation Sequencing (NGS) biomarker panel—can cost between RM8,000 and RM15,000+ at private hospitals. Once treatment starts, oral targeted therapy drugs (such as first-, second-, or third-generation EGFR or ALK inhibitors) typically cost between RM4,500 and RM15,000+ per month depending on the specific drug generation and dosage protocol, with hospital fee schedules listing even baseline first-generation TKIs at RM4,700 to RM5,800 per month.
  • How Medical Insurance (Medical Cards) Helps: A hospitalisation and surgical medical card is designed to reimburse or directly settle actual medical bills at panel hospitals. Depending on your policy’s annual limit and cancer outpatient benefit terms, a medical card typically covers:
    • Inpatient hospitalisation, ICU care, and surgical tumour resection (such as lobectomy or VATS).
    • Diagnostic biopsies and staging scans leading to a confirmed cancer diagnosis.
    • Eligible outpatient cancer treatments, including radiotherapy, intravenous chemotherapy, immunotherapy, and approved oral targeted therapies.
  • How Critical Illness (CI) Coverage Complements Your Medical Card: While a medical card pays the hospital, it does not pay for your mortgage, groceries, or out-of-pocket caregiving costs. A Critical Illness plan pays out a tax-free lump sum of cash directly to you upon a confirmed diagnosis of covered cancer. This lump sum gives you the financial flexibility to:
    • Replace lost income if you or a family caregiver need to take time off work.
    • Fund advanced molecular profiling tests, non-panel medications, or nutritional and rehabilitative support not fully covered by a standard medical card.
  • Building Financial Stamina for Long-Term Recovery: Studies in Malaysia show that nearly half of cancer survivors spend over a third of their household income within the first year of diagnosis. Adequate medical and critical illness coverage provides the financial stamina for long-term treatments, ensuring that patients can stay on effective targeted therapies continuously without depleting their family savings.

Frequently Asked Questions

Why is lung cancer in non-smokers increasing in Malaysia?

Lung cancer in non-smokers is frequently driven by acquired genetic mutations—most notably the EGFR mutation, which occurs in approximately 40% to over 60% of Malaysian lung adenocarcinoma patients and is especially prevalent among Asian women who have never smoked. Environmental triggers such as prolonged exposure to secondhand cigarette smoke, seasonal haze and PM2.5 air pollution, indoor cooking oil fumes in poorly ventilated kitchens, and occupational toxins also contribute to cellular DNA damage in the lungs.

Who should get a low-dose CT lung screening in Malaysia?

In Malaysia, low-dose CT (LDCT) lung screening is recommended for adults aged 45 to 75 who have a history of smoking (typically 20 pack-years or more) or long-term vaping, as well as former smokers who quit within the past 15 years. Additionally, never-smokers within this age bracket who have a first-degree family history of lung cancer (a parent, sibling, or child) or chronic occupational exposure to lung carcinogens should consult a doctor about getting a baseline LDCT scan.

Can stage 4 lung cancer targeted therapy cure the disease?

Stage 4 lung cancer—meaning the cancer has spread to distant organs—is generally not considered curable. However, for patients with specific genetic biomarkers like EGFR or ALK mutations, targeted therapy can shrink tumours, halt disease progression for years, and transform advanced lung cancer into a manageable chronic condition. Because targeted pills focus on mutated cancer cells while sparing healthy tissue, patients typically experience fewer side effects and enjoy a much higher quality of life than with conventional chemotherapy.

Does vaping carry the same lung cancer risk as smoking cigarettes?

While e-cigarettes do not burn tobacco leaf or produce tar like conventional cigarettes, vaping is not risk-free. E-cigarette aerosols contain ultrafine particles, volatile organic compounds, carcinogenic aldehydes (such as formaldehyde and acrolein), and heavy metals like nickel, tin, and lead from the heating coil. Inhaling these chemicals deep into the lungs causes chronic airway inflammation and cellular DNA damage, which are established pathways for long-term lung disease and cancer risk.

This article is for reference only; the actual coverage terms are subject to the policy.

This article is for reference only and is not medical advice. Please consult a registered doctor if you have any concerns.

Share
The above information was provided by Bowtie Team. It is for reference only. In no event shall Bowtie be liable to you or to any other party for any loss or damage whatsoever or howsoever caused directly or indirectly in connection with your access to or use of the content thereon.

Related Articles

Health

Balanitis: Symptoms, Causes, Medical Treatments, and Prevention

Health

Colorectal Cancer: Screening, Symptoms, Costs, Stages, Survival Rates & Prevention Guide

Health

Bone Cancer: Symptoms, Diagnosis, Treatments & Care

Other Topics

Email

General Enquiry
hello@bowtie.com.hk
Media Enquiry
media@bowtie.com.hk
Partnership
partner@bowtie.com.hk

© 2026 Bowtie Life Insurance Company Limited. All rights reserved.

Your Browser is outdated. To have a better user experience, please upgrade or change another browsers. OK